内容

目次

Clinical presentation and cognitive dysfunction in schizophrenia, N.C.Andreasen et al; Genetic and environmental risk factors for schizophrenia, J.Yakeley, R. M. Murray; Neurodevelopmental aspects of schizophrenia: thegenetically-determined trajectory to 'hemispheric indecision', T.J. Crow,D.J. Done; Neuropsychological and QEEG mapping correlates ofpsychopathological dimensions in drug-free schizophrenic patients, S.Galderisi et al; The significance of brain morphological findings to thetreatment of schizophrenia, L.E. DeLisi; Brain morphological abnormalitiesand the clinical outcome of schizophrenia, A. Vita et al; Changes in rCBFHMPAO-SPECT studies according to the course of schizophrenic illness, L.Ravizza et al; Schizophrenia and intracortical 'dysconnection': new insightsabout pathophysiology: new insights about pathophysiology and mechanisms ofantipsychotic treatment, J.H. Callicott III, D.R. Weinberger; The dopamine D3receptor and schizophrenia: pharmacological, anatomical and geneticapproaches, P. Sokoloff et al; Presynantic autoreceptors modulatingdopaminergic activity: pharmacology and therapeutic implications, A.Carlsson; Preclinical tests that predict clozapine-like atypicalantipsychotic actions, J.M. Goldstein; Regulation of dopamine D2-likereceptor subtypes following chronic typical or atypical neuroleptictreatment, F.J. Tarazi et al; Treatment effects on the course ofschizophrenia: potential benefits of atypical antipsychotics in first episodepatients, J. A. Liebeman; Outcome measures for antypsychotic drug treatment,H.Y. Meltzer; Expressed emotion and schizophrenia: from measurement totreatment, J. Leff; Psychoeducation and relapse prevention, an update, M.J.Goldstein; Extrapyramidal side effects of neuroleptic medication: focus onrisperidone, H.J. Moller; The pharmacological treatment of schizophrenia:safety and compliance issues, W.W. Fleischhacker; Is there a relationshipbetween extrapyramidal disorders and efficacy: fact or fiction? G.D.Tollefson et al; The safety and tolerability of ziprasidone treatment, K.P.Gunn et al; The treatment of resistant schizophrenia: a pilot , open study onthe treatment with risperidone and clozapine, R. Cavallaro et al; Healtheconomic aspects on the treatment of schizophrenia, E. Lindstrom et al;Economic assessment of neuroleptic strategies in schizophrenia, E. Souetre.